The present invention is directed to ultrafiltration devices, and more particularly to a portable ultrafiltration device that may be continuously worn by a patient.
Fluid overload can be caused by many things including metabolic disease, renal failure and, especially, congestive heart failure (CHF), which has become a disease of epidemic proportions all over the globe. CHF is a progressive deterioration of the heart muscle that leads to an inability to pump enough blood to support the vital organs. Deterioration of the heart muscle leads to decreased pumping capacity and increased fluid retention caused by the lack of perfusion pressure of the kidneys due to the failure of the heart to pump enough blood at the proper pressure. Fluid overload can cause leg swelling, shortness of breath and water accumulation in the lungs, impairing the ability to properly breathe.
Removal of excess fluids from the body can be accomplished with diuretics and other drugs that improve the performance of the heart muscle. However, these drugs become gradually ineffective over time and may cause undesirable effects such as kidney failure. In addition, there is a growing body of research supporting the notion that fluid removal by ultrafiltration may be superior to the administration of very large doses of diuretic drugs.
Advantages of ultrafiltration over diuretic drugs include: (1) efficient fluid removal without side effects such as kidney failure and blood pressure drops; (2) prompt relief from shortness of breath and swelling; and (3) improvement regarding certain adverse hormonal effects that are associated with CHF.
Ultrafiltration is performed by pumping blood from a catheter in an artery or a large vein, through a blood filter or a dialyzer, while creating a gradient of pressure through the filter membrane. The pressure gradient forces the passage of fluid out of the blood by convection and the fluid is drained out.
Conventional ultrafiltration devices suffer from several drawbacks. Usually, these devices are cumbersome, heavy and must be hooked to electrical outlets. Since ultrafiltration patients must remain connected to these devices for many hours, their ability to perform normal every day activities is severely limited. In addition, typical ultrafiltration treatments are geared for fast removal of several liters of excess fluid. However, the fluid removal is only temporary and the excess fluid usually reaccumulates in the patient's body after a short period of time. The reaccumulation of fluid is harmful to the patients, as the kidneys are further injured by the progress of CHF and the side effects of the diuretic drugs used to treat the heart.
A further problem with ultrafiltration devices is that repeated reconnection to an ultrafiltration device requires accessing blood flow by puncturing a large blood vessel and forming an arteriovenous shunt. These shunts only last for limited periods of time and are subject to infection, clotting and other complications that result in numerous hospitalizations and repeated surgical interventions. Similar problems also exist when a patient's blood stream is accessed by alternative methods, such as by inserting large catheters into large veins and arteries.
In view of the above disadvantages, there is a substantial need for a portable ultrafiltration device that provides continual, steady and smooth removal of excess fluid from the body.
The present invention alleviates to a great extent the above-noted and other disadvantages by providing a portable, wearable ultrafiltration device that performs continuous, steady and smooth removal of excess fluid from the body. Importantly, this ultrafiltration device does not require a patient to be hooked up to a large machine for many hours a day, several days per week. Instead, the ultrafiltration device can conveniently be worn on a patient's body for continual use, 24 hours a day, seven days a week, providing steady and smooth removal of excess fluid from the body and preventing the shortness of breath and swelling that are associated with CHF.
One aspect of the present invention involves an ultrafiltration device adapted to be worn on a portion of the body of a patient, including a blood pump and a blood filter for separating excess fluid from the blood.
A further aspect of the present invention involves an ultrafiltration device in the form of a belt adapted to be worn about the waist, shoulder, thigh or other body portion of a patient, wherein the belt includes a pair of end portions which are secured together by a belt fastening means.
Another aspect of the present invention involves an ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir from which anticoagulants are infused into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.
These and other features and advantages of the present invention will be appreciated from review of the following detailed description of the invention, along with the accompanying figures in which like reference numerals refer to like parts throughout.
Ultrafiltration is a process by which excess fluid in the form of water is removed from the blood, wherein the excess fluid in the blood is moved from one side of a filtering device to another. The filtering device contains many hollow fibers made out of a semipermeable membrane. While blood flows inside of the hollow fibers, water from the blood moves through the membrane wall and is drained off. The purified blood remains inside the hollow fibers and is returned to the body.
Referring to
The ultrafiltration device 10 comprises a belt 20 adapted to be worn about a portion of the body of the patient. According to some embodiments, the ultrafiltration device 10 is adapted to be worn about the waist of the patient. However, as would be understood to those of ordinary skill in the art, the device 10 may also be worn about other portions of the patient's body, such as over a shoulder or around a thigh. According to some embodiments, the weight of the belt 30 is less than two pounds.
As seen in
The blood filter 30 separates excess fluid from the patient's blood. The excess fluid is drained in to an excess fluid bag 50, which is to be periodically emptied via tap 90. The fluid bag 50 can be positioned in the vicinity of a thigh, a leg, an ankle, an arm, or any other suitable body portion of the patient.
The coagulation of the blood circulating through the device 10 is prevented by the constant infusion of anticoagulant, which is infused from an anticoagulant reservoir 95 through a port 105 and into the blood inlet tube 33. In some embodiments, anticoagulant is infused using a battery powered anticoagulant pump 115. The pump 115 may be a shuttle pump, piston pump, roller pump, centrifuge pump, piezoelectric pump, or other convention pump. Typical anticoagulants are infused into the blood 150 include, but are not limited to, heparin, prostacyclin, low molecular weight heparin, hirudin and sodium citrate. According to other embodiments, blood clotting inside the device 10 can be prevented by the oral administration of anticoagulent drugs including, but not limited to, coumadin.
Referring to
The blood 150 moves through the hollow fibers 310 under pressure from the blood pump 60. This pressure causes the excess fluid 135 in the blood 150 to filter out through the fiber pores, into the other side of the hollow fibers 310, from where the excess fluid 135 is drained out to the fluid bag 50. The magnitude of pressure within the fibers 310 determines the amount of net excess fluid 135 movement removed through exterior walls 350. Small particles within the blood 150 are also removed during this process, but particles larger than the blood filter pore size will be left behind in the blood 150.
Referring to
Referring to
Referring to
Thus, it is seen that a wearable ultrafiltration device is provided. One skilled in the art will appreciate that the present invention can be practiced by other than the preferred embodiments which are presented in this description for purposes of illustration and not of limitation, and the present invention is limited only by the claims that follow. It is noted that equivalents for the particular embodiments discussed in this description may practice the invention as well.
This application is a continuation-in-part of U.S. patent application Ser. No. 10/085,349, filed Nov. 16, 2001, now U.S. Pat. No. 6,960,179, issued on Nov. 1, 2005, which is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
3388803 | Scott | Jun 1968 | A |
3746175 | Markley | Jul 1973 | A |
3884808 | Scott | May 1975 | A |
3902490 | Jacobsen et al. | Sep 1975 | A |
3989622 | Marantz et al. | Nov 1976 | A |
3994799 | Yao et al. | Nov 1976 | A |
4000072 | Sato et al. | Dec 1976 | A |
4094775 | Mueller | Jun 1978 | A |
4118314 | Yoshida | Oct 1978 | A |
4209392 | Wallace | Jun 1980 | A |
4212738 | Henne | Jul 1980 | A |
4247393 | Wallace | Jan 1981 | A |
4267040 | Schäl | May 1981 | A |
4269708 | Bonomini et al. | May 1981 | A |
4326955 | Babb et al. | Apr 1982 | A |
4443333 | Mahurkar | Apr 1984 | A |
4563170 | Aigner | Jan 1986 | A |
4765907 | Scott | Aug 1988 | A |
4806247 | Schoendorfer et al. | Feb 1989 | A |
4828543 | Weiss et al. | May 1989 | A |
4897189 | Greenwood et al. | Jan 1990 | A |
4950395 | Richalley | Aug 1990 | A |
4968422 | Runge et al. | Nov 1990 | A |
4997570 | Polaschegg | Mar 1991 | A |
5284470 | Beltz | Feb 1994 | A |
5284559 | Lim et al. | Feb 1994 | A |
5360445 | Goldowsky | Nov 1994 | A |
5391143 | Kensey | Feb 1995 | A |
5405320 | Twardowski et al. | Apr 1995 | A |
5415532 | Loughnane et al. | May 1995 | A |
5545131 | Davankov | Aug 1996 | A |
5577891 | Loughnane et al. | Nov 1996 | A |
5725776 | Kenley et al. | Mar 1998 | A |
5876419 | Nederlof | Mar 1999 | A |
5902336 | Mishkin | May 1999 | A |
5944684 | Roberts et al. | Aug 1999 | A |
5980481 | Gorsuch | Nov 1999 | A |
5984891 | Keilman et al. | Nov 1999 | A |
6117100 | Powers et al. | Sep 2000 | A |
6117122 | Din et al. | Sep 2000 | A |
6168578 | Diamond | Jan 2001 | B1 |
6196922 | Sherman et al. | Mar 2001 | B1 |
6196992 | Keilman et al. | Mar 2001 | B1 |
6325774 | Bene et al. | Dec 2001 | B1 |
6332985 | Sherman et al. | Dec 2001 | B1 |
6406631 | Collins et al. | Jun 2002 | B1 |
6491673 | Palumbo et al. | Dec 2002 | B1 |
6561997 | Weitzel et al. | May 2003 | B1 |
6610036 | Branch et al. | Aug 2003 | B2 |
6632192 | Gorsuch et al. | Oct 2003 | B2 |
6685664 | Levin et al. | Feb 2004 | B2 |
6706007 | Gelfand et al. | Mar 2004 | B2 |
6758975 | Peabody et al. | Jul 2004 | B2 |
6776912 | Baurmeister | Aug 2004 | B2 |
6796955 | O'Mahony et al. | Sep 2004 | B2 |
6843779 | Andrysiak et al. | Jan 2005 | B1 |
6890315 | Levin et al. | May 2005 | B1 |
7033498 | Wong | Apr 2006 | B2 |
7309323 | Gura | Dec 2007 | B2 |
7351218 | Bene | Apr 2008 | B2 |
20020112609 | Wong | Aug 2002 | A1 |
20030236482 | Gorsuch et al. | Dec 2003 | A1 |
20060241543 | Gura | Oct 2006 | A1 |
Number | Date | Country |
---|---|---|
1051303 | May 1991 | CN |
20113789 | May 2002 | DE |
2585251 | Jan 1987 | FR |
2124511 | Feb 1984 | GB |
Number | Date | Country | |
---|---|---|---|
20030097087 A1 | May 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10085349 | Nov 2001 | US |
Child | 10251937 | US |